239 related articles for article (PubMed ID: 35180899)
1. Radionanomedicine: Advanced Strategy for Precision Theranostics of Breast Cancer.
Guo Y; Liu X
J Biomed Nanotechnol; 2022 Jan; 18(1):50-60. PubMed ID: 35180899
[TBL] [Abstract][Full Text] [Related]
2. All-in-One Nanomedicine: Multifunctional Single-Component Nanoparticles for Cancer Theranostics.
Cai Y; Chen X; Si J; Mou X; Dong X
Small; 2021 Dec; 17(52):e2103072. PubMed ID: 34561968
[TBL] [Abstract][Full Text] [Related]
3. Advanced nanomedicine and cancer: Challenges and opportunities in clinical translation.
Gonzalez-Valdivieso J; Girotti A; Schneider J; Arias FJ
Int J Pharm; 2021 Apr; 599():120438. PubMed ID: 33662472
[TBL] [Abstract][Full Text] [Related]
4. Radionanomedicine: widened perspectives of molecular theragnosis.
Lee DS; Im HJ; Lee YS
Nanomedicine; 2015 May; 11(4):795-810. PubMed ID: 25645957
[TBL] [Abstract][Full Text] [Related]
5. Theranostic small interfering RNA nanoparticles in cancer precision nanomedicine.
Chen Z; Krishnamachary B; Pachecho-Torres J; Penet MF; Bhujwalla ZM
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Mar; 12(2):e1595. PubMed ID: 31642207
[TBL] [Abstract][Full Text] [Related]
6. Stimuli-activatable nanomedicine meets cancer theranostics.
Li H; Feng Y; Luo Q; Li Z; Li X; Gan H; Gu Z; Gong Q; Luo K
Theranostics; 2023; 13(15):5386-5417. PubMed ID: 37908735
[TBL] [Abstract][Full Text] [Related]
7. Recent Advances in Theranostic Applications of Nanomaterials in Cancer.
Ahmed F; Khan MA; Haider N; Ahmad MZ; Ahmad J
Curr Pharm Des; 2022; 28(2):133-150. PubMed ID: 34530703
[TBL] [Abstract][Full Text] [Related]
8. Bioresponsive Nanomedicine: The Next Step of Deadliest Cancers' Theranostics.
Mao Y; Liu X
Front Chem; 2020; 8():257. PubMed ID: 32328480
[TBL] [Abstract][Full Text] [Related]
9. Polymer Vesicles: Modular Platforms for Cancer Theranostics.
Wang F; Xiao J; Chen S; Sun H; Yang B; Jiang J; Zhou X; Du J
Adv Mater; 2018 Apr; 30(17):e1705674. PubMed ID: 29450915
[TBL] [Abstract][Full Text] [Related]
10. Theranostic Nanomedicine; A Next Generation Platform for Cancer Diagnosis and Therapy.
Sharma R; Mody N; Agrawal U; Vyas SP
Mini Rev Med Chem; 2017; 17(18):1746-1757. PubMed ID: 26891932
[TBL] [Abstract][Full Text] [Related]
11. Ultrasound-based nanomedicine for molecular imaging of prostate cancer: from diagnostics to theranostics.
Zhu Y; Sun Y; Duan Y; Chen Y
Nanomedicine (Lond); 2021 Oct; 16(23):2029-2032. PubMed ID: 34519535
[No Abstract] [Full Text] [Related]
12. Recent Advances in Metal-Phenolic Networks for Cancer Theranostics.
Zhang Z; Xie L; Ju Y; Dai Y
Small; 2021 Oct; 17(43):e2100314. PubMed ID: 34018690
[TBL] [Abstract][Full Text] [Related]
13. Positron emission tomography and nanotechnology: A dynamic duo for cancer theranostics.
Goel S; England CG; Chen F; Cai W
Adv Drug Deliv Rev; 2017 Apr; 113():157-176. PubMed ID: 27521055
[TBL] [Abstract][Full Text] [Related]
14. Precision biomaterials in cancer theranostics and modelling.
Caballero D; Abreu CM; Lima AC; Neves NN; Reis RL; Kundu SC
Biomaterials; 2022 Jan; 280():121299. PubMed ID: 34871880
[TBL] [Abstract][Full Text] [Related]
15. Theranostic nanoparticles for the management of thrombosis.
Russell P; Hagemeyer CE; Esser L; Voelcker NH
Theranostics; 2022; 12(6):2773-2800. PubMed ID: 35401833
[TBL] [Abstract][Full Text] [Related]
16. Challenges and opportunities in the development of metal-based anticancer theranostic agents.
Vaidya SP; Gadre S; Kamisetti RT; Patra M
Biosci Rep; 2022 May; 42(5):. PubMed ID: 35420649
[TBL] [Abstract][Full Text] [Related]
17. Cancer Nanotheranostics: A Nanomedicinal Approach for Cancer Therapy and Diagnosis.
Kundu P; Singh D; Singh A; Sahoo SK
Anticancer Agents Med Chem; 2020; 20(11):1288-1299. PubMed ID: 31429694
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive approach of hybrid nanoplatforms in drug delivery and theranostics to combat cancer.
Thorat ND; Townley HE; Patil RM; Tofail SAM; Bauer J
Drug Discov Today; 2020 Jul; 25(7):1245-1252. PubMed ID: 32371139
[TBL] [Abstract][Full Text] [Related]
19. Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.
Farolfi A; Fendler W; Iravani A; Haberkorn U; Hicks R; Herrmann K; Walz J; Fanti S
Eur Urol Oncol; 2019 Mar; 2(2):152-162. PubMed ID: 31017091
[TBL] [Abstract][Full Text] [Related]
20. Nanoparticle theranostics in cardiovascular inflammation.
MacRitchie N; Di Francesco V; Ferreira MFMM; Guzik TJ; Decuzzi P; Maffia P
Semin Immunol; 2021 Aug; 56():101536. PubMed ID: 34862118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
